7,8-Benzoflavone
7,8-Benzoflavone is one of the most potent inhibitors of breast cancer resistance protein (BCRP).
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J. Soc. Cosmet. Sci. Korea2021, 47(1):57-63
Food Res Int.2019, 123:125-134
Molecules.2019, 24(2):329
Plant Physiol Biochem.2021, 160:166-174.
Biomolecules.2020, 10(6):925.
Mol Biol Rep.2024, 51(1):56.
J Ethnopharmacol.2024, 335:118628.
Biomed Pharmacother.2024, 181:117658.
Int J Mol Sci.2020, 21(19),7070.
J Cell Biochem.2018, 119(2):2231-2239
Related and Featured Products
J Pharm Sci. 2008 Oct;97(10):4546-56.
Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats.[Pubmed:
18257033 ]
The flavonoid 7,8-Benzoflavone was recently identified as one of the most potent inhibitors of breast cancer resistance protein (BCRP); however, little is known of the in vivo disposition of 7,8-Benzoflavone. The objective of this study was to investigate the pharmacokinetics and bioavailability of 7,8-Benzoflavone in rats.
METHODS AND RESULTS:
Three intravenous (5, 10, and 25 mg/kg) and three oral (12.5, 25, and 50 mg/kg) doses were administered to female Sprague-Dawley rats. Plasma samples were analyzed by high-performance liquid chromatography. Pharmacokinetic analysis was conducted by WinNonlin and ADAPT II. The dose-normalized plasma concentration versus time curves did not superimpose with each other, indicating the nonlinear pharmacokinetics of 7,8-Benzoflavone. 7,8-Benzoflavone exhibited a large volume of distribution (V(ss) approximately 1.5 L/kg) and rapid oral absorption (t(max) < 30 min). The bioavailability of 7,8-Benzoflavone was low (0.61-13.2%) and dose-dependent. A pharmacokinetic model with dose-dependent bioavailability, linear absorption and nonlinear elimination best described the pharmacokinetic profiles of 7,8-Benzoflavone.
CONCLUSIONS:
Using a 50 mg/kg oral dose of 7,8-Benzoflavone, we could significantly increase the AUC for the BCRP substrate nitrofurantoin, demonstrating the potential for BCRP-mediated drug interactions.
